News | August 07, 2007

Emageon Reports Net Positive Cash Flow in 2Q07

August 8, 2007 – Emageon Inc. reported financial results for its second quarter ended June 30, 2007, reflecting net positive operating cash flow of $3.7 million for the second quarter of 2007, an improvement of $7.7 million over net negative operating cash flow of $4.0 million in first quarter 2007. For the six months ended June 30, 2007, net cash used in operations was $0.3 million. At June 30, 2007, cash and marketable securities totaled $20.9 million, compared to $23.0 million at December 31, 2006.

“We are encouraged by our recent sales momentum, as our bookings improved substantially in the second quarter compared to first quarter”, said Chuck Jett, Chairman, CEO, and President of Emageon. “We are also pleased that our cash earnings and cash flow from operations were very positive in the second quarter.”

Revenue for the quarter was $25.6 million, a 14.8% decrease from second quarter 2006 revenue of $30.0 million. The net loss for the quarter was $0.3 million, or $0.01 per share, including $0.6 million, or $0.03 per share, in expenses related to the Company’s previously announced May 2007 reduction in workforce. In the second quarter of 2006, the Company had a net loss of $0.9 million, or $0.04 per share. The second quarter 2006 net loss included $1.1 million, or $0.05 per share, in expenses related to the integration of Camtronics Medical Systems, Ltd. (“Camtronics”) into the company’s operations. The Company acquired Camtronics November 1, 2005.

Revenue for the six months ended June 30, 2007 was $52.9 million, a decrease of 7.2% from first half 2006 revenue of $57.0 million. Net loss for the six months ended June 30, 2007 was $2.1 million, or $0.10 per share, including the second quarter restructuring charge described above. For the six months ended June 30, 2006, the Company’s net loss was $7.9 million, or $0.38 per share, including $2.3 million, or $0.11 per share, in expenses related to the integration of Camtronics.

The Company’s earnings excluding non-cash charges for depreciation, amortization of intangible assets and stock-based compensation (“cash earnings”) were $2.7 million, or $0.13 per share, in second quarter 2007 compared to $3.0 million, or $0.14 per share, in second quarter 2006. For the six months ended June 30, 2007, the Company’s cash earnings were $4.0 million, or $0.18 per diluted share, compared to a loss of $0.4 million, or $0.02 per share, for the six months ended June 30, 2006. These measures of earnings were not determined in accordance with generally accepted accounting principles (“GAAP”). A reconciliation of earnings determined under GAAP to earnings exclusive of non-cash charges is included below.

Emageon also announced today that the Company’s available secured line of credit from its commercial bank was increased in early August from $10 million to $15 million with no significant changes in terms. No amounts were outstanding under this line at June 30, 2007.

For more information: www.emageon.com

Related Content

The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents| November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents| November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents| November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents| October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents| January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents| November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
OCT stent strut coverage

OCT imaging showing neointimal tissue coverage of metallic stent struts.

News | Stents| November 07, 2016
November 7, 2016 – Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
biosensors Biofreedom stent
News | Stents| November 07, 2016
November 7, 2016 – The two-year results from LEADERS FREE, the first randomized clinical trial dedicated to high blee
Overlay Init